Sarda Proteins Ltd Upgraded to Sell on Technical Improvements Despite Fundamental Challenges

Technical Trend Reversal Spurs Upgrade

The most significant catalyst behind the rating change is the improvement in the company’s technical profile. The technical grade shifted from mildly bearish to mildly bullish, reflecting a more optimistic market sentiment. Key indicators on the weekly charts such as MACD and RSI have turned bullish, signalling potential upward momentum. Specifically, the weekly MACD is bullish while the monthly MACD remains mildly bearish, indicating short-term strength amid longer-term caution.

Other technical tools reinforce this view: Bollinger Bands on the weekly timeframe are bullish, daily moving averages support a positive trend, and the KST (Know Sure Thing) indicator is bullish weekly, though bearish monthly. Dow Theory assessments on both weekly and monthly charts are mildly bullish, suggesting a tentative but improving trend. However, On-Balance Volume (OBV) shows no clear trend, indicating volume support remains uncertain.

This technical improvement is reflected in the stock’s recent price performance. Sarda Proteins closed steady at ₹97.78 on 14 July 2026, with a 52-week range between ₹59.95 and ₹137.45. The stock has outperformed the Sensex significantly over multiple periods, delivering a 31.94% return year-to-date compared to the Sensex’s negative 8.92%. Over three and five years, the stock’s returns of 112.57% and 209.43% respectively dwarf the Sensex’s 17.49% and 46.71% gains, highlighting strong relative momentum despite its micro-cap status.

Valuation Remains Expensive Despite Discount to Peers

While the technical outlook has improved, valuation metrics continue to weigh on the stock’s appeal. Sarda Proteins trades at a high Price to Book (P/B) ratio of 29.2, signalling a very expensive valuation relative to its book value. This is compounded by a Return on Equity (ROE) of 20.9%, which, although robust, does not justify the steep valuation in the eyes of many investors.

However, the stock is currently trading at a discount compared to its peers’ historical valuations, suggesting some relative value within the edible oil sector. This nuanced valuation picture contributes to the cautious Sell rating rather than a more positive Buy or Strong Buy recommendation.

Financial Trend Shows Mixed Signals

On the financial front, Sarda Proteins posted its highest quarterly profits in Q4 FY25-26, with PBDIT and PBT less other income both reaching ₹0.60 crore, and PAT hitting ₹0.84 crore. These results indicate a positive short-term financial trend and improved profitability.

Nevertheless, the company’s long-term financial health remains fragile. Its average Return on Capital Employed (ROCE) over the past five years is a weak 4.20%, reflecting limited efficiency in generating returns from capital invested. Net sales have grown at a modest annual rate of 4.87%, while operating profit growth has been even slower at 2.29% annually over the same period.

Debt servicing ability is a significant concern, with an average EBIT to interest coverage ratio of just 0.07, indicating the company struggles to comfortably meet interest obligations. This weak financial trend tempers enthusiasm despite recent quarterly gains.

Quality Assessment Highlights Structural Weaknesses

The company’s quality grade remains low, consistent with its micro-cap status and financial challenges. The MarketsMOJO Mojo Score stands at 43.0, categorised as a Sell grade, upgraded from a previous Strong Sell. This score reflects the combined impact of weak fundamentals and improving technicals.

Sarda Proteins is part of the edible oil industry and sector, which faces competitive pressures and margin volatility. The company’s micro-cap market capitalisation further adds to risk, as liquidity and institutional interest tend to be limited.

Technicals Drive Upgrade Amidst Fundamental Caution

The upgrade from Strong Sell to Sell is a reflection of the nuanced picture investors face with Sarda Proteins. The technical indicators have improved markedly, signalling a potential short-term recovery or stabilisation in price action. This is a key factor in the rating change, as technicals often guide near-term trading decisions.

However, the company’s fundamental metrics remain underwhelming. Weak long-term growth, poor capital efficiency, and limited debt servicing capacity continue to constrain the stock’s outlook. The expensive valuation relative to book value also suggests limited upside from current levels without a meaningful improvement in fundamentals.

Investors should weigh the positive quarterly earnings and technical momentum against the structural challenges and valuation risks. The stock’s strong relative returns over recent years demonstrate potential for gains, but caution is warranted given the underlying financial fragility.

Outlook and Investor Considerations

For investors considering Sarda Proteins, the current Sell rating indicates that while the stock is no longer a strong sell, it is not yet a compelling buy. The technical improvement may offer trading opportunities, but the fundamental backdrop suggests a cautious approach.

Given the micro-cap status and volatile sector dynamics, investors should monitor upcoming quarterly results and any shifts in debt servicing ability closely. A sustained improvement in ROCE and operating profit growth would be necessary to justify a more positive rating in the future.

Meanwhile, the stock’s valuation premium and weak long-term financial trends remain key risks. Those seeking exposure to the edible oil sector might consider higher-quality or better-valued alternatives until Sarda Proteins demonstrates more consistent fundamental progress.

Summary

Sarda Proteins Ltd’s investment rating upgrade to Sell from Strong Sell on 13 July 2026 is primarily driven by a turnaround in technical indicators, including bullish weekly MACD, RSI, and moving averages. Despite this, the company’s fundamentals remain weak, with low ROCE, modest sales and profit growth, and poor debt coverage. Valuation is expensive with a P/B of 29.2, though the stock trades at a discount to peers’ historical valuations. Recent quarterly earnings were positive, but long-term financial health and quality metrics continue to limit upside potential. Investors should approach the stock with caution, balancing technical optimism against fundamental risks.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today